Table 1

Characteristics of the 17 included studies. There were 9 crossover and 8 parallel studies. The isoflavones tablets introduced were mainly in aglycone form. The abbreviations were listed below table.
Study
 Treatment (Rx) †
 Isoflavones content in Rx (mg/d) ‡
 Control
 Isoflavones content in control (mg/d)
 No. of subjects
 Lipid status §
 Subject gender ||
 Length of treatment (weeks)
*Calvert 1981 [7]
 soy biscuits
 NA
 soy biscuits
 0
 10
 H
 male
 4
Clifton-Bligh 2001(I) [8]
 T
 57
 T




Clifton-Bligh 2001(II) [8]
 T
 85.5
28.5
 46
 B
 female
 26
Dewell 2002 [9]
 T
 150 G = 40; D = 50; glycosides = 60
 placebo
 0
 36
 H
 female
 24
Hale 2002 [10]
 T
 80 G = 40; D = 40
 placebo
 0
 29
 NS
 post
 2
Han 2002 [11]
 soy protein capsule
 100 G = 70; D = 18; glycitein = 12
 soy protein capsule
 0
 78
 N
 peri
 16
Hodgson 1998 [12]
 T
 55 G = 30; D = 1; B = 16; F = 8
 placebo
 0
 59
 N
 male & female
 8
Howes 2000 [13]
 T
 40 G = 1; D = 0.5; B = 26; F = 16
 placebo
 0
 75
 NS
 post
 5
Mackey 2000 [14]
 ISP
 65
 ISP
 < 4
 49
 H
 post
 12
*Merz-Demlow 2000(I) [15]
 ISP
 113–144
 ISP




*Merz-Demlow 2000(II) [15]
 ISP
 55–74
9–11
 13
 N
 female
 3
*Nestel 1997 [16]
 T
 40–80 G= 22–43; D = 17–33; glycitein= 1–3
 placebo
 0
 21
 B
 female
 5
*Nestel 1999(I) [17]
 T
 80 G = 8; D = 7; B = 49; F = 16
 placebo




*Nestel 1999(II) [17]
 T
 40 G = 4; D = 3.5; B = 24.5; F = 8
0
 13
 B
 female
 5
*Samman 1999 [18]
 T
 86 G = 8.6; D = 7.4; B = 51.4; F = 18.6
 placebo
 0
 14
 N
 pre
 16
*Sanders 2002 [19]
 soy burger
 56 G = 34.8; D = 21.2
 soy burger
 2
 22
 N
 male & female
 2
*Simons 2000 [20]
 T
 80
 placebo
 0
 20
 N
 post
 8
Squadrito 2002 [21]
 T
 54 G= 54
 placebo
 0
 60
 N
 female
 24
*Urban 2001 [22]
 T
 70 G = 42; D = 27
 ISP
 3
 28
 N
 elderly men
 6
*Wangen 2001(I) [23]
 ISP
 110–154
 ISP




*Wangen 2001(II) [23]
 ISP
 54–76
6–8.2
 18
 NS
 post
 4

* crossover design † 'T' = isoflavone tablet; 'ISP' = isolated soy protein ‡ 'G' = Genistein; 'D' = Daidzein; 'B' = Biochanin A; 'F' = Formononectin §'H' = hyperlipidemic subjects, 'N' = normolipidemic subjects; 'B' = both hyper- and normolipidemic subjects; 'NS' = not specified || 'pre' = premenopausal women; 'peri' = perimenopausal women; 'post' = postmenopausal women

Yeung and Yu Nutrition Journal 2003 2:15   doi:10.1186/1475-2891-2-15

Open Data